Guardant Health Reports the Availability of Guardant Reveal Liquid Biopsy Test for the Detection of Residual Disease and Recurrence of Early-Stage Breast and Lung Cancers
- The company reported the expansion of the Guardant Reveal test that detects minimal residual disease in patients with stage II and III CRC, breast & lung cancer
- The test enhances early-stage cancer patient management by detecting ctDNA in blood after surgery without the need for a tissue biopsy & identifying patients with MRD who have a higher risk for recurrence and may benefit from additional therapy
- The test will be initiated as soon as 3wks. after surgery. The test has also been demonstrated to predict disease recurrence more accurately than current SoC methods like carcinoembryonic antigen (CEA) tests which are only partially capable of identifying patients with a high risk of recurrence
Ref: Guardant | Image: Guardant Health
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.